Dyne Hopes DM1 And DMD Mid-Stage Data Can Lead To Accelerated Approval

 
• By Joseph Haas

Phase I/II data for its ADC candidates in myotonic dystrophy type 1 and Duchenne muscular dystrophy indicate potential for biomarker-based accelerated approval in both diseases, Dyne asserts.

Expediting
Dyne plans to pursue accelerated approved in both DM1 and DMD • Source: Shutterstock

More from Strategy

More from Business